Clinical Trials Directory

Trials / Completed

CompletedNCT00110461

Aripiprazole in Children and Adolescents With Bipolar I Disorder

A Phase III Trial to Test the Safety and Efficacy of Two Doses of Aripiprazole in Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
296 (actual)
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
Sex
All
Age
10 Years – 17 Years
Healthy volunteers
Not accepted

Summary

The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.

Conditions

Interventions

TypeNameDescription
DRUGAripiprazoleTreatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
DRUGAripiprazoleTreatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
DRUGplaceboPlacebo tablet

Timeline

Start date
2005-03-01
Primary completion
2007-02-01
Completion
2007-02-01
First posted
2005-05-10
Last updated
2012-05-21
Results posted
2012-05-21

Locations

53 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00110461. Inclusion in this directory is not an endorsement.